BSG guidance recommends switching to biosimilar infliximab

Home/Guidelines | Posted 26/02/2016 post-comment0 Post your comment

The British Society of Gastroenterology (BSG) released new guidance in February 2016 recommending that stable patients be switched to biosimilar infliximab (CT-P13).

Remsima V14A10

Biosimilar infliximab, Remisima/Inflectra (CT-P13), received marketing authorization in June 2013 [1]. The clinical trials used to support this authorization were carried out in rheumatoid arthritis and ankylosing spondylitis. Controlled trials of CT-P13 were not undertaken in Crohn’s disease (CD) or ulcerative colitis (UC). However, evidence for clinical benefit in inflammatory bowel disease has been obtained from several post-marketing studies. The BSG has therefore concluded that there is sufficient data from observational studies to show that safety and clinical efficacy of CT-P13 are comparable to the originator drug, with similar immunogenicity, and that switching from Remicade to CT-P13 is also safe and effective.

The BSG therefore recommends that ‘patients who are in a stable clinical response or remission on Remicade therapy can be switched to Remsima or Inflectra at the same dose and dose interval’.

Other recommendations made by the society include:

  • Infliximab must be prescribed by brand name, i.e. Remicade, Remsima or Inflectra, and not by International Nonproprietary Name (INN).
  • For patients starting infliximab: Remicade, Remsima or Inflectra can be prescribed, taking into account the evidence showing similar clinical effectiveness.
  • Automatic substitution at the pharmacy level without consulting the prescriber is not appropriate.
  • Pharmacovigilance is essential for any new biological medicine, and patients prescribed Remsima or Inflectra should be followed for safety, in a registry such as the UK National IBD Registry.

Related articles
Finnish drug regulator recommends interchangeability of biosimilars 

Updated guideline on the use of epoetin and darbepoetin in cancer patients

1.  GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 26]. Available from:  

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: BSG

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010